Brian F. Chapin, MD
Department of Urology, Division of Surgery
Education & Training
Degree-Granting Education
| 2004 | Georgetown University School of Medicine, Washington, DC, USA, MD, Medicine |
| 2000 | Siena College, Loudonville, NY, USA, BS, Biology |
Postgraduate Training
| 2010-2012 | Clinical Fellowship, Urologic Oncology, UT MD Anderson Cancer Center, Houston, TX |
| 2006-2009 | Clinical Residency, Urology, Massachusetts General Hospital, Boston, MA |
| 2005-2006 | Clinical Residency, General Surgery, Massachusetts General Hospital, Boston, MA |
| 2004-2005 | Clinical Internship, General Surgery, Massachusetts General Hospital, Boston, MA |
Board Certifications
| 2014 | American Board of Urology |
Experience & Service
Academic Appointments
Director of Clinical Research, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2023
Administrative Appointments/Responsibilities
Rotation Site Director, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Administrative Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2011
Administrative Chief Resident, Massachusetts General Hospital, Boston, MA, 2008 - 2009
Administrative Chief Resident, Children's Hospital Boston, Boston, MA, 2008 - 2008
Honors & Awards
| 2019 | SUO 2019 Young Investigator Award, SUO Award Committee |
| 2016 - 2017 | Teacher Of The Year, UT MD Anderson Cancer Center |
| 2015 | Distinguished Educator Award, UT MD Anderson Cancer Center |
| 2007 | Harvard Medical School Resident Teaching Award, Massachusetts General Hospital |
| 2004 | Cum Laude, Georgetown University School of Medicine |
| 2000 | Summa Cum Laude, Siena College, Loundonville, New York |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology 155:144-151, 2021. e-Pub 2021. PMID: 33676955.
- Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol 80(3):389-390, 2021. e-Pub 2021. PMID: 33824032.
- Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol 18(6):337-358, 2021. e-Pub 2021. PMID: 33824525.
- Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YA. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer 127(9):1425-1431, 2021. e-Pub 2021. PMID: 33721334.
- Tang C, Lei X, Smith GL, Pan HY, Hoffman KE, Kumar R, Chapin BF, Shih YT, Frank SJ, Smith BD. Influence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys 109(5):1286-1295, 2021. e-Pub 2020. PMID: 33316361.
- Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int 127(3):340-348, 2021. e-Pub 2020. PMID: 32357283.
- Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer 127(5):720-728, 2021. e-Pub 2021. PMID: 33411364.
- Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol 79(2):298-306, 2021. e-Pub 2020. PMID: 33279304.
- Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?. J Clin Oncol 39(1):13-16, 2021. e-Pub 2020. PMID: 33048621.
- Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased frequency of Mesorectal and Perirectal LN involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys 107(5):982-985, 2020. e-Pub 2020. PMID: 32353391.
- Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer 126(16):3667-3673, 2020. e-Pub 2020. PMID: 32453443.
- Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol 10(4):282-292, 2020. e-Pub 2020. PMID: 32298794.
- Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int 125(6):792-800, 2020. e-Pub 2020. PMID: 32176456.
Invited Articles
- Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?. AJR Am J Roentgenol 214(6):1248-1258, 2020. e-Pub 2020. PMID: 32130049.
- Chapin B, McGuire S, Aparicio A. Local Therapy in Metastatic Prostate Cancer: Does an Integrated Approach Improve Clinical Outcomes?. 2015 Genitourinary Cancers Symposium Daily News, 2015.
Editorials
- Khaled D, Chapin BF. Determining the Key to Sucess for Radical Prostatectomy: Is There a Surrogate Measure for a Meaningful Clinical Outcome? RE: Groeben et al. World J Urol.
- Chapin BF, McGuire SE, Aparicio A. Is Treatment of the Primary Tumor in Metastatic Prostate Cancer Justified?. Eur Urol 65(6):1067-8, 2014. PMID: 24411278.
Abstracts
- Ranasinghe W, Brooks N, Elseshtawi M, Davis J, Bathala T, Troncoso P, Aparicio A, Tu SM, Chapin BF. Patterns of Metastases of Prostatic Ductal Adenocarcinoma. 20th Annual Meeting of the Society of Urologic Oncology (SUO), 2019.
- Amado JZ, Tidwell RS, Troncoso P, Chapin BF, Harris D, Pister LL, Araujo JC, Pettaway CA, Aparicio A, T SM, Papadopoulos JN, Wang J, Logothetis C, Pagliaro LC, Davis JW. Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis. 2019 ASCO Annual Meeting, 2019.
- Aparicio A, Zhang M, Ramesh N, Wang X, Corn PG, Zurita AJ, Davis JW, Pettaway CA, Adibi M, McGuire SE, Tu SM, Wang J, Subudhi SK, Elsheshtawai M, Efsthathiou E, Logothetis C, Navin N, Troncoso P, Chapin BF. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). 2019 ASCO Annual Meeting, 2019.
- Chapin BF, Wang X, Zhang M, Corn PG, Zurita AJ, Elsheshtawi M, Davis JW, Pettaway CA, Adibi M, Gleave M, Cooperberg MR, Smaldone MC, McGuire SE, Tu SM, Wang J, Subudhi SK, Efstathiou E, Logothetis C, Troncoso P, Aparicio A. Local Therapy for de novo Metastatis Prostate Cancer - Who, Why, When?. 2019 ASCO Annual Meeting, 2019.
- Altok M, Chapin B, Matin S, Achim M, Davis J. Omitting A Lymph Node Dissection At Radical Prostatectomy: Are There Consequences For Unexpected Upgrading/Upstaging?. AUA 2019, 2019.
- Ajay D, Li H, Barrett-Harlow B, Nguyen J, Benson C, Wang X, Chapin B, Davis J, Westney OL. Perioperative Factors Contributing The Delayed Return To Continence After Radical Prostatectomy. AUA 2019, 2019.
- Reichard C, Duplisea J, Nyame Y, Sundi D, Tosoian J, Achim M, Wilkins L, Alam R, Stephenson A, Klein E, Ross A, Allaf M, Davis J, Chapin B. Clinically Significant Gleason 8 Downgrading in Sub-Stratified High Risk Prostate Cancer Occurs Infrequently. 19th Annual Meeting of the Society of Urologic Oncology (SUO), 2018.
- Gregg JR, Zheng J, Lopez D, Reichard C, Chapin B, Kim J, Daivs J, Daniel C. Diet Quality and Disease progression Among Localized Prostate Cancer Patients on Active Surveillance. 19th Annual Meeting of the Society of Urologic Oncology (SUO), 2018.
- Oke O, Tang C, Shaaban S, Xiao L, Reichard CA, Chapin BF, Anscher MS, Aparicio A. Impact of definitive local therapy (LT) in men with primary small cell (or poorly differentiated neuroendocrine) prostate carcinomas (pSCPC). 2018 ASCO Annual Meeting, 2018.
- Reichard CA, Gregg J, Achim MF, Aparicio A, Pister LL, Ward JF, Davis JW, Chapin BF. Radical prostatectomy in metastatic castration-resistant prostate cancer: Feasibility, safety, and quality of life outcomes. 2018 Genitourinary Cancers Symposium, 2018.
Book Chapters
- Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban D, Efstathiou E, Aparicio A. Neoplasms of the Prostate. In: Holland-Frei Cancer Medicine. 9th, 2017.
- Chapin BF. Positive Surgical Margins: How to Self-Evaluate and Improve. In: Robot-Assisted Radical Prostatectomy: Beyond the Learning Curve. Springer.
Patient Reviews
CV information above last modified July 16, 2024